Skip to main content

Outside the X bubble of software developers and tokenmaxers, how are non-technical professionals actually using AI in production to run real, revenue-generating businesses?


If you scroll tech Twitter, the discourse is dominated by "tokenmaxing" — people flexing multi-million token usage, chaining complex autonomous agent loops, and obsessing over API token throughput. But far away from that hype, how does AI function in a real enterprise setting where revenue, accuracy, and client relationships are on the line?

I recently had a deep conversation with a medical professional who offers a grounded perspective missing from mainstream tech discussions. He is a co-founder of a medical communications agency based in Jeddah, working face-to-face with major pharmaceutical companies and healthcare professionals. His agency bridges the gap between medical science and advertising — building research-backed, highly regulated campaigns.

Having worked in the industry for over a decade — spanning 9-to-5 corporate roles, freelancing, and now running an agency — his experience provides a clear benchmark for where AI provides genuine leverage, where it exposes businesses to risk, and why human intuition remains irreplaceable.

1. The Real-World Stack: $20 Plan

Tokenmaxers talk about burning millions/billions of tokens building complex multi-agent frameworks. In reality, his agency's production setup isn't complex at all: it centers around a standard $20/month Claude Pro subscription paired with the Claude Code Chrome plugin.

Here is how that $20 investment generates real operational ROI:

  • Admin Automation via Browser Integration: By pointing the Claude Code Chrome plugin directly at his agency's internal worker portal, AI figures out routine administrative workflows on the fly. It automatically calculates his commissions — a task that previously swallowed hours of tedious manual labor without requiring any specialized medical expertise. Getting those hours back has been a massive operational win.
  • Literature Analysis & Synthesizing Data: He feeds medical papers and research journals into Claude to extract key insights, summarize clinical trials, and run preliminary analysis to ground advertising claims in solid data.
  • Force Multiplier for Production: AI acts as a multi-discipline assistant. As a technical medical writer by trade, AI allows him to generate visual concepts, draft preliminary copy, and create campaign imagery — effectively turning a single professional into a full-spectrum production unit.

2. The Hallucination That Almost Cost a Big Account

While AI accelerates the initial research phase, he emphasizes that AI cannot be trusted blindly in high-stakes industries.

Recently, a major client asked for a campaign strictly aligned with Saudi medical regulatory guidelines. The AI generated a clean, persuasive breakdown. However, when he personally double-checked the raw source documentation, he discovered that the AI had completely omitted critical local guidelines.

Had his team blindly trusted the output, they would have delivered non-compliant work to a high-stakes account, risking severe fines and damaged credibility. In regulated industries like healthcare, AI makes the collection and formatting phase 10x faster, but human verification remains 100% non-negotiable.

3. The Experience Factor & The Managerial "Sniff Test"

Why can't AI simply replace a senior professional with a decade of experience? Because domain expertise isn't just a list of technical, step-by-step instructions — it's taste, judgment, and tacit knowledge built over years of handling clients and navigating industry nuances.

As an agency owner evaluating daily submissions from staff, he easily spots lazy AI outputs:

"If a designer or writer relies lazily on Claude without customizing it or applying their own judgment, I can immediately sniff it out. The output feels typical, template-driven, and generic."

AI can synthesize information, but it lacks the contextual taste that separates average work from compelling, high-converting campaigns.

4. The Palantir Paradox: Surrendering Your "Secret Sauce"

Our discussion touched on a deeper strategic dilemma that many agency owners face: the risk of handing your proprietary business logic over to third-party AI platforms.

Palantir CEO Alex Karp has recently highlighted that when enterprise businesses feed their core processes, internal data interconnections, and workflows into frontier AI models, they risk handing over their "secret sauce." Over time, these AI platforms can absorb the domain expertise of the agency itself — potentially commoditizing or replacing the very businesses that trained them.

5. Automation Anxiety vs. The Economics of Human Labor

Like many professionals watching the rapid convergence of Large language models and automated systems, he expressed concern about technology overhauling white-collar and blue-collar work alike.

However, a practical economic counter-argument exists: in many industries, deploying advanced autonomous pipelines and specialized hardware remains significantly more expensive than employing skilled humans. Until the unit economics of hardware, inference, and error-remediation drop dramatically, human labor remains both economically viable and qualitatively superior for nuanced work.

Conclusion: Real Execution Over Tokenmaxing

People using AI to execute real client work outside the coding bubble aren't tokenmaxing on social media. They aren't flexing token burn rates or farming engagement with prompt lists; they are quietly using a $20 tool and smart browser integrations to reclaim their time, expand their individual output, and navigate high-stakes client relationships.

This conversation was the first step in a broader casual research project. I plan to conduct a series of semi-structured interviews with professionals across the healthcare and marketing sectors to document how other industries experience, critique, and adapt to AI in the wild.

Comments

Popular posts from this blog

Trying to Speed Up a Weird Neural Net Idea on My Mac's GP

I've been playing around with a transformer variant where, instead of one shared feed-forward layer, every single neuron gets its own tiny private network. It's a fun idea, but the first version I wrote ran painfully slow on my Mac, and this post is basically my notes on figuring out why, and what I tried to fix it. The Setup The model has 3 layers and around 2,574 "neurons" at full size (I mostly tested a shrunk-down version with way fewer, just to iterate faster). Each neuron has its own small 2-layer MLP with its own weights — nothing is shared between neurons at this stage. Each layer does roughly: Normal causal self-attention A regular shared MLP that mixes information across neurons The weird part: each of the ~2,574 neurons runs through its own tiny 2-layer network, completely independently for each neuron n: h = GELU( x[n] * in_w[n] + in_b[n] ) h = GELU( LN( h @ hw0[n] + hb0[n] ) * lw0[n] + lb0[n] ) + h h = GELU( LN( h @ hw1[n] + hb1[...

Shovels, Chatbots, and the AI Bubble Nobody Else Is In

I talked to a pharma executive last week. Big company, UK based, he runs things from what I think is the Middle East control room in Jeddah. Senior guy, more than a decade in the industry. I asked him the obvious question, how is he using AI day to day. He does not, not really. He uses Copilot to proofread emails and juggle the occasional idea, because Copilot is the only thing his work laptop will let him touch. He told me he thought about running a second laptop off the company firewall so he could actually explore what is out there, but keeping two work laptops was too much of a hassle. So he stayed on one laptop, inside the firewall, and stayed a chatbot user. That is not a story about one lazy executive. That is a story about an entire class of sectors, heavy IP, heavy security, heavy regulation, where the friction of adopting anything beyond a sanctioned chatbot is high enough that the frontier simply does not reach them yet. Pharma, medicine, anywhere production touches actu...